RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
-4.26%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$1.49B
AUM Growth
+$1.49B
(-6.3%)
Cap. Flow
+$12.7M
Cap. Flow
% of AUM
0.85%
Top 10 Holdings %
Top 10 Hldgs %
30.22%
Holding
143
New
5
Increased
55
Reduced
19
Closed
10
Top Buys
| 1 |
UnitedHealth
UNH
|
$26.4M |
| 2 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$24.2M |
| 3 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
$12.5M |
| 4 |
Bristol-Myers Squibb
BMY
|
$11.7M |
| 5 |
Merck
MRK
|
$9.57M |
Top Sells
| 1 |
Pfizer
PFE
|
$35.8M |
| 2 |
HCA Healthcare
HCA
|
$32.5M |
| 3 |
McKesson
MCK
|
$13.7M |
| 4 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$6.83M |
| 5 |
GI
EndoChoice Holdings, Inc.
GI
|
$5.77M |
Sector Composition
| 1 | Healthcare | 81.35% |
| 2 | Financials | 4.56% |
| 3 | Industrials | 0.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Penumbra
PEN
$10.5B
| $18.9M | 1.26% |
295,500
+29,000
| +11% | +$1.85M |
|
27
Incyte
INCY
$17B
| $16.9M | 1.13% |
169,000
+12,500
| +8% | +$1.25M |
|
|
PRAH
28
DELISTED
PRA Health Sciences, Inc.
PRAH
| $16.5M | 1.11% |
300,000
+47,000
| +19% | +$2.59M |
|
29
Neurocrine Biosciences
NBIX
$13.5B
| $15.9M | 1.06% |
410,000
| – | – |
|
|
AMRN
30
Amarin Corp
AMRN
$311M
| $15.4M | 1.03% |
4,991,500
+35,754
| +0.7% | +$110K |
|
|
WMGI
31
DELISTED
Wright Medical Group Inc
WMGI
| $15.3M | 1.03% |
667,000
+54,000
| +9% | +$1.24M |
|
32
Prothena Corp
PRTA
$452M
| $15.2M | 1.02% |
309,500
+1,500
| +0.5% | +$73.8K |
|
33
Amgen
AMGN
$153B
| $14.1M | 0.94% |
96,500
+2,500
| +3% | +$366K |
|
34
Coherus Oncology, Inc. Common Stock
CHRS
$146M
| $13.6M | 0.91% |
484,500
+17,000
| +4% | +$479K |
|
35
Jazz Pharmaceuticals
JAZZ
$7.99B
| $13.5M | 0.9% |
123,700
+16,700
| +16% | +$1.82M |
|
36
Galapagos
GLPG
$2.06B
| $13.5M | 0.9% |
210,000
| – | – |
|
37
Willis Towers Watson
WTW
$31.9B
| $13.5M | 0.9% |
110,000
+51,500
| +88% | +$6.3M |
|
38
Biogen
BIIB
$20.8B
| $13.3M | 0.89% |
47,000
-11,000
| -19% | -$3.12M |
|
|
WBA
39
DELISTED
Walgreens Boots Alliance
WBA
| $13.3M | 0.89% |
161,000
| – | – |
|
|
RARX
40
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $12.5M | 0.84% |
+826,000
| New | +$12.5M |
|
41
Danaher
DHR
$143B
| $12.5M | 0.83% |
160,000
| – | – |
|
|
PTHN
42
DELISTED
Patheon N.V.
PTHN
| $11.5M | 0.77% |
400,000
| – | – |
|
43
Edwards Lifesciences
EW
$47.7B
| $11.3M | 0.76% |
120,500
+17,250
| +17% | +$1.62M |
|
44
Ultragenyx Pharmaceutical
RARE
$3.04B
| $11.2M | 0.75% |
159,750
+12,750
| +9% | +$896K |
|
|
DERM
45
DELISTED
Dermira, Inc.
DERM
| $11M | 0.74% |
362,600
+7,600
| +2% | +$231K |
|
46
Encompass Health
EHC
$12.5B
| $10.9M | 0.73% |
265,000
| – | – |
|
47
Hologic
HOLX
$14.7B
| $10.6M | 0.71% |
265,000
+12,500
| +5% | +$502K |
|
48
BioMarin Pharmaceuticals
BMRN
$11.3B
| $10.4M | 0.69% |
125,000
| – | – |
|
49
TherapeuticsMD
TXMD
$12.7M
| $9.92M | 0.66% |
1,720,000
-80,000
| -4% | -$462K |
|
50
Travere Therapeutics
TVTX
$1.75B
| $9.88M | 0.66% |
522,000
| – | – |
|